Glenmark Pharmaceuticals Declines 4.78%: 4 Key Factors Behind the Weekly Slide

1 June: Bearish Sentiment Evident as Put Option Activity Surges

Glenmark Pharmaceuticals emerged as the most active stock in put options trading on 1 June 2026, signalling heightened bearish sentiment among investors ahead of the 30 June expiry. The stock closed at ₹2,201.20, down 3.21% from the previous close, underperforming the Sensex which fell 0.96% that day.

Put options with a strike price of ₹2,200 saw 1,971 contracts traded, generating a turnover of approximately ₹569.87 lakhs and an open interest of 757 contracts. This activity suggests investors were either hedging existing positions or speculating on further downside, reflecting caution despite Glenmark’s strong fundamentals and a Mojo Score of 81.0.

Technically, the stock traded below its short-term moving averages but remained above its 100-day and 200-day averages, indicating long-term support amid short-term weakness. Delivery volumes surged to 6.74 lakh shares, a 156.27% increase over the five-day average, highlighting active repositioning by institutional and retail investors.

2 June: Mixed Signals from Q4 Results and Technical Indicators

On 2 June, Glenmark reported an exceptional Q4 FY26 quarter, though marred by a sequential decline compared to previous quarters. The stock closed at ₹2,184.90, down 0.74%, while the Sensex gained 0.43%, underscoring stock-specific pressures.

Technical momentum shifted from bullish to mildly bullish, with mixed signals from key indicators. The weekly MACD turned mildly bearish, while the monthly MACD remained bullish, reflecting a divergence between short- and long-term trends. The RSI hovered in neutral territory, and volume indicators showed no decisive trend, suggesting consolidation rather than a clear directional move.

The Mojo Grade was downgraded from Strong Buy to Buy on 1 June, with a current Mojo Score of 71.0, signalling a tempered outlook despite the company’s strong fundamentals and multi-year outperformance versus the Sensex.

Valuation Adjustments Reflect Market Volatility and Sector Dynamics

Also on 2 June, Glenmark’s valuation profile shifted from very attractive to attractive amid ongoing market volatility. The price-to-earnings (P/E) ratio stood at 22.03, while the price-to-book value (P/BV) ratio was 5.92, both remaining competitive within the Pharmaceuticals & Biotechnology sector.

Other multiples such as EV to EBIT (15.41) and EV to EBITDA (13.48) indicated a balanced valuation, with the company trading at a premium but not excessively so. Glenmark’s return on capital employed (ROCE) of 40.27% and return on equity (ROE) of 26.86% supported the premium multiples, alongside a low PEG ratio of 0.18 signalling growth at a reasonable price.

Compared to peers, Glenmark’s valuation remains attractive relative to companies like Mankind Pharma and Laurus Labs, which trade at much higher multiples. The recent downgrade in Mojo Grade from Strong Buy to Buy reflects a more cautious stance rather than a fundamental deterioration.

4 June: Minor Recovery Amid Low Volumes

On 4 June, Glenmark’s stock price edged up 0.36% to ₹2,181.45, recovering slightly from earlier losses. This modest gain occurred on relatively low volume of 10,788 shares, suggesting limited conviction behind the move. The Sensex also rose 0.19%, indicating a broadly positive market environment.

This day’s price action aligned with the mildly bullish technical indicators observed earlier in the week, though the overall trend remained cautious given the preceding declines.

5 June: Week Ends with Continued Downward Pressure

The week concluded on 5 June with Glenmark’s stock closing at ₹2,165.50, down 0.73% on the day and marking a 4.78% decline for the week. The Sensex also fell 0.10%, but Glenmark’s underperformance was more pronounced, reflecting persistent bearish sentiment and profit-taking.

Volume surged to 45,631 shares, indicating renewed investor activity as the week closed. The stock’s price remained below key short-term moving averages, reinforcing the cautious technical outlook.

Key Takeaways

Bearish positioning and technical caution: The surge in put option activity at the ₹2,200 strike price early in the week highlighted investor concerns about near-term downside risk, coinciding with the stock’s underperformance versus the Sensex.

Mixed technical momentum: While the long-term monthly MACD and Bollinger Bands remain bullish, weekly indicators and short-term moving averages signal mild bearishness or consolidation, suggesting a cautious trading environment.

Valuation recalibration: The shift from very attractive to attractive valuation metrics reflects market volatility and price adjustments, though Glenmark’s strong ROCE, ROE, and low PEG ratio continue to support its fundamental appeal.

Volume and price action: Delivery volumes and trading activity showed spikes on key days, indicating active repositioning by investors amid uncertainty, with the stock closing the week near its lows.

Conclusion

Glenmark Pharmaceuticals Ltd. faced a challenging week marked by a 4.78% decline in its stock price, underperforming the broader market. The combination of increased bearish sentiment in the options market, mixed technical signals, and a valuation shift to a more cautious stance contributed to the subdued performance. Despite these headwinds, the company’s strong fundamentals, including robust profitability and a solid Mojo Grade of Buy, provide a foundation for potential recovery once market volatility subsides. Investors should continue to monitor technical developments and sector dynamics closely as the stock navigates this consolidation phase.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →